IL285232B - Preparations containing oleandrin for the treatment of viral infection - Google Patents

Preparations containing oleandrin for the treatment of viral infection

Info

Publication number
IL285232B
IL285232B IL285232A IL28523221A IL285232B IL 285232 B IL285232 B IL 285232B IL 285232 A IL285232 A IL 285232A IL 28523221 A IL28523221 A IL 28523221A IL 285232 B IL285232 B IL 285232B
Authority
IL
Israel
Prior art keywords
acid
antiviral composition
oleandrin
salt
antiviral
Prior art date
Application number
IL285232A
Other languages
English (en)
Hebrew (he)
Other versions
IL285232A (en
Original Assignee
Phoenix Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/051553 external-priority patent/WO2018053123A1/en
Application filed by Phoenix Biotechnology Inc filed Critical Phoenix Biotechnology Inc
Publication of IL285232A publication Critical patent/IL285232A/en
Publication of IL285232B publication Critical patent/IL285232B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL285232A 2017-09-14 2018-07-16 Preparations containing oleandrin for the treatment of viral infection IL285232B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2017/051553 WO2018053123A1 (en) 2016-09-14 2017-09-14 Method and compositions for treating viral infection
US201862698365P 2018-07-16 2018-07-16
PCT/US2018/042226 WO2019055119A1 (en) 2017-09-14 2018-07-16 METHOD AND COMPOSITION FOR TREATING VIRAL INFECTION

Publications (2)

Publication Number Publication Date
IL285232A IL285232A (en) 2021-09-30
IL285232B true IL285232B (en) 2022-07-01

Family

ID=65723839

Family Applications (2)

Application Number Title Priority Date Filing Date
IL285232A IL285232B (en) 2017-09-14 2018-07-16 Preparations containing oleandrin for the treatment of viral infection
IL273162A IL273162B (en) 2017-09-14 2020-03-09 Preparations containing oleandrin for the treatment of viral infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL273162A IL273162B (en) 2017-09-14 2020-03-09 Preparations containing oleandrin for the treatment of viral infection

Country Status (9)

Country Link
EP (1) EP3681508A4 (de)
JP (3) JP6820450B2 (de)
KR (2) KR20210107904A (de)
AU (2) AU2018334386B2 (de)
CA (1) CA3075729A1 (de)
IL (2) IL285232B (de)
MX (1) MX2020002883A (de)
RU (1) RU2020113341A (de)
WO (1) WO2019055119A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
SG11202105728YA (en) 2020-03-31 2021-11-29 Phoenix Biotechnology Inc Method and compositions for treating coronavirus infection
EP4009981B1 (de) 2020-03-31 2023-08-16 Phoenix Biotechnology, Inc. Verfahren und zusammensetzungen zur behandlung von coronavirusinfektionen
ES2965161T3 (es) * 2020-03-31 2024-04-11 Phoenix Biotechnology Inc Método y composiciones para el tratamiento de infección por coronavirus
FR3109297A1 (fr) * 2020-04-19 2021-10-22 Ephyla « Nouvel inhibiteur non protéique de furine »
WO2022094816A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation
US20230310612A1 (en) * 2022-04-01 2023-10-05 Alexia Reif Anti-viral composition and method for preparing the same

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT84857B (pt) 1986-05-13 1990-02-08 Huseyin Ziya Ozel Processo para a preparacao de extractos de plantas da especie nerium e de composicoes farmaceuticas que os contem
US5236132A (en) 1992-01-03 1993-08-17 Vortec, Inc. Gradient-force comminuter/dehydrator apparatus and method
US5598979A (en) 1995-04-20 1997-02-04 Vortec, Inc. Closed loop gradient force comminuting and dehydrating system
CA2191923C (en) 1996-12-03 2000-10-24 Ji-Won Yoon Portulaca oleracea and tumor cell growth
CN1307473A (zh) 1998-05-19 2001-08-08 研究发展基金会 三萜组合物和它们的使用方法
US6565897B2 (en) 1998-09-24 2003-05-20 Ozelle Pharmaceuticals, Inc. Extract of nerium species, pharmaceutical composition thereof and methods for preparation thereof
US6517015B2 (en) 2000-03-21 2003-02-11 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
AU2001284946B2 (en) 2000-08-18 2007-02-01 Advanced Life Sciences Inc. Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV
US9931316B2 (en) * 2004-01-06 2018-04-03 Paul Edward Stamets Antiviral activity from medicinal mushrooms and their active constituents
US6715705B2 (en) 2001-03-16 2004-04-06 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
ATE295087T1 (de) 2001-04-09 2005-05-15 Loders Croklaan Bv Konzentrat von triterpenen
EP1476031A1 (de) 2001-05-11 2004-11-17 University of Ottawa Angstlösende zusammensetzungen der marcgraviaceae enthaltend betulinsäure, deren derivate und verfahren
US20040082521A1 (en) 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
AU2003240818B2 (en) * 2002-05-28 2006-05-04 Bette Pollard Cardiac glycosides to treat cystic fibrosis and other IL-8 dependent disorders
EP1585504A4 (de) 2002-11-06 2009-07-15 Azaya Therapeutics Inc Proteinstabilisierte liposomale formulierungen pharmazeutischer wirkstoffe
US20050026849A1 (en) 2003-03-28 2005-02-03 Singh Chandra U. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
US20050239748A1 (en) 2004-03-17 2005-10-27 Panacos Pharmaceuticals, Inc. Pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
US7118508B2 (en) 2004-07-28 2006-10-10 General Motors Corporation Planetary transmissions having three interconnected gear members and clutched input members
AU2005327442B2 (en) 2005-02-09 2011-09-01 Dabur Pharma Limited Novel betulinic acid derivatives a-ring-condensed to a heterocyclic group
CA2603124A1 (en) 2005-03-29 2006-10-05 Regents Of The University Of Minnesota Selective oxidation of triterpenes employing tempo
US20060252733A1 (en) 2005-04-07 2006-11-09 Novelix Pharmaceuticals, Inc. Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism
US20090131714A1 (en) 2005-06-08 2009-05-21 Krasutsky Pavel A Synthesis of betulonic and betulinic aldehydes
CA2611435C (en) 2005-06-10 2013-01-08 Pola Chemical Industries Inc. Novel triterpenic acid derivative and preparation for external application for skin comprising the same
US7402325B2 (en) * 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
CA2633402A1 (en) 2005-12-16 2007-07-12 Panacos Pharmaceuticals, Inc. Preparation of pharmaceutical salts of 3-o-(3',3'-dimethlsuccinyl) betulinic acid
EP1803461A1 (de) * 2005-12-27 2007-07-04 Heinz-Herbert Fiebig Therapeutische Verwendung eines Nerium-oleander Blätterextrakts
GB0604535D0 (en) 2006-03-07 2006-04-12 Sndv Sprl Betulonic acid derivatives
US20090203661A1 (en) 2006-10-12 2009-08-13 Safe Stephen H Betulinic acid, derivatives and analogs thereof and uses therefor
AR063546A1 (es) 2006-11-03 2009-01-28 Panacos Pharmaceuticals Inc DERIVADOS DE TRITERPENO, METODOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE INFECCIoN POR EL VIRUS VIH.
WO2008091532A1 (en) 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
US8987212B2 (en) 2007-08-07 2015-03-24 Muhammed Majeed Oleanoyl peptide composition and method of treating skin aging
EP2231165B1 (de) 2007-11-13 2013-05-15 Phoenix Biotechnology Inc. Verfahren zur bestimmung der wahrscheinlichkeit einer therapeutischen antwort bei der krebs-chemotherapie mit herzglykosid
BRPI0911422B8 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
CN102164941B (zh) 2008-04-18 2015-05-27 里亚塔医药公司 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
PL2276493T3 (pl) 2008-04-18 2019-05-31 Reata Pharmaceuticals Inc Antyoksydacyjne modulatory stanu zapalnego: pochodne kwasu oleanolowego z amino- i innymi modyfikacjami przy C-17
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CA2736568A1 (en) 2008-09-10 2010-03-18 Universite Du Quebec A Chicoutimi Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
CN101704872B (zh) 2009-11-23 2012-06-27 张南 23-羟基白桦酸衍生物、其制备方法及应用
WO2011064710A1 (en) 2009-11-30 2011-06-03 University Of Kwazulu-Natal In vitro anti-sickling activity of betulinic acid, oleanolic acid and their derivatives
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
WO2011085307A1 (en) 2010-01-11 2011-07-14 Phoenix Biotechnology, Inc. Method of treating neurological conditions with cardiac glycosides
TWI386415B (zh) 2010-02-02 2013-02-21 Univ Kaohsiung Medical 熊果酸衍生物及其醫藥組合物
TWI410431B (zh) 2010-12-22 2013-10-01 Ind Tech Res Inst 齊敦果酸衍生物在製備預防或治療ｃ型肝炎之藥物的用途
WO2012095705A1 (en) 2011-01-10 2012-07-19 Hetero Research Foundation Pharmaceutically acceptable salts of novel betulinic acid derivatives
PL2670764T3 (pl) 2011-01-31 2016-02-29 Bristol Myers Squibb Co C-28 aminy zmodyfikowanych C-3 pochodnych kwasu betulinowego jako inhibitory dojrzewania HIV
CN102558280B (zh) 2011-11-18 2014-09-17 温州大学 一种30-卤代桦木酸的生产方法
JP6043361B2 (ja) 2011-12-01 2016-12-14 ハンジョウ ベンシェン ファーマシューティカル シーオー．， エルティーディー．Ｈａｎｇｚｈｏｕ Ｂｅｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． オレアノール酸アミド化誘導体、その調製方法及び使用
DK2786757T3 (da) 2011-12-01 2017-11-20 Hangzhou Bensheng Pharmaceutical Co Ltd 2-substitueret oleanolsyre-derivat, fremgangsmåde til fremstilling af samme, og anvendelse deraf
US20150119373A1 (en) 2012-04-24 2015-04-30 Hetero Research Foundation Novel betulinic acid derivatives as hiv inhibitors
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
CN104684883A (zh) 2012-08-14 2015-06-03 内克索利戈有限公司 新型乌索酸衍生物及其制备方法
WO2014040056A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
PE20150627A1 (es) 2012-09-10 2015-06-04 Reata Pharmaceuticals Inc Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
WO2014105926A1 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Novel betulinic acid proline derivatives as hiv inhibitors
BR112015019590A2 (pt) 2013-02-25 2017-07-18 Bristol Myers Squibb Co derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
WO2015121168A1 (de) * 2014-02-12 2015-08-20 Organobalance Gmbh Hefe-stamm und mikrobielles verfahren zur produktion von pentazyklischen triterpenen und/oder triterpenoiden
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
US9492438B2 (en) * 2014-07-25 2016-11-15 Bette Pollard Amphiphilic pyridinum compounds to treat epilepsy and other disorders of the nervous system
MX2017015670A (es) * 2015-06-08 2018-08-15 Dermarc LLC Composicion terapeutica.

Also Published As

Publication number Publication date
JP7037673B2 (ja) 2022-03-16
EP3681508A1 (de) 2020-07-22
AU2020204236B2 (en) 2020-12-10
KR102295179B1 (ko) 2021-08-30
CA3075729A1 (en) 2019-03-21
EP3681508A4 (de) 2021-05-19
KR20210107904A (ko) 2021-09-01
WO2019055119A1 (en) 2019-03-21
RU2020113341A3 (de) 2021-10-15
IL285232A (en) 2021-09-30
AU2018334386A1 (en) 2020-04-02
RU2020113341A (ru) 2021-10-15
JP2021063105A (ja) 2021-04-22
JP6820450B2 (ja) 2021-01-27
IL273162A (en) 2020-04-30
IL273162B (en) 2021-08-31
JP2020534293A (ja) 2020-11-26
MX2020002883A (es) 2020-10-05
JP2022075755A (ja) 2022-05-18
AU2018334386B2 (en) 2021-11-04
AU2020204236A1 (en) 2020-07-16
KR20200081356A (ko) 2020-07-07

Similar Documents

Publication Publication Date Title
EP3512524B1 (de) Verfahren und zusammensetzungen zur behandlung von virusinfektionen
US10596186B2 (en) Method and compositions for treating viral infections
AU2020204236B2 (en) Method and composition for treating viral infection
US10729735B1 (en) Method and compostitions for treating coronavirus infection
US11324789B2 (en) Method and compositions for treating equine encephalitis
IL291727B2 (en) Method and preparations for treating the corona virus infection
US20220047616A1 (en) Method and Compositions for Treating HTLV-1 Virus Infection
CA3091376C (en) Method and compositions for treating coronavirus infection
EP4295854A2 (de) Verfahren und zusammensetzungen zur behandlung von coronavirusinfektionen